Journey Medical (DERM) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Journey Medical is set to release its Q2 2025 earnings on August 11th, with analysts expecting a loss of ($0.06) per share and revenue of $14.93 million.
• The company previously reported a loss of ($0.18) per share for Q1 2025, surpassing expectations and achieving revenue of $13.14 million.
• Journey Medical's stock has a market cap of $163.79 million and recently opened at $7.03, with analysts issuing mixed ratings on its shares.

Journey Medical (NASDAQ:DERM - Get Free Report) is expected to announce its Q2 2025 earnings results after the market closes on Tuesday, August 12th. Analysts expect Journey Medical to post earnings of ($0.06) per share and revenue of $14.93 million for the quarter.

Journey Medical (NASDAQ:DERM - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.06. Journey Medical had a negative return on equity of 52.03% and a negative net margin of 14.76%. The firm had revenue of $13.14 million for the quarter, compared to analysts' expectations of $12.05 million. On average, analysts expect Journey Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Journey Medical Price Performance

NASDAQ DERM traded up $0.27 during trading on Friday, hitting $7.57. 71,427 shares of the stock traded hands, compared to its average volume of 98,081. The company has a quick ratio of 1.03, a current ratio of 1.34 and a debt-to-equity ratio of 1.07. Journey Medical has a 12-month low of $3.54 and a 12-month high of $8.25. The firm has a 50-day simple moving average of $7.14 and a 200-day simple moving average of $6.38. The company has a market capitalization of $176.38 million, a P/E ratio of -19.41 and a beta of 0.80.

Hedge Funds Weigh In On Journey Medical

Several hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in shares of Journey Medical during the first quarter valued at $110,000. Geode Capital Management LLC grew its holdings in Journey Medical by 130.7% during the 2nd quarter. Geode Capital Management LLC now owns 262,353 shares of the company's stock worth $1,884,000 after acquiring an additional 148,612 shares in the last quarter. Finally, Creative Planning increased its position in Journey Medical by 178.5% during the 2nd quarter. Creative Planning now owns 32,764 shares of the company's stock valued at $235,000 after purchasing an additional 21,000 shares during the period. Institutional investors own 7.25% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wall Street Zen cut Journey Medical from a "buy" rating to a "hold" rating in a research note on Sunday, July 6th. Alliance Global Partners reissued a "buy" rating on shares of Journey Medical in a research report on Thursday, May 15th.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.